Bictegravir/lenacapavir - Gilead Sciences
Alternative Names: GS-6207/GS-9883; GS-9883/GS-6207; Lenacapavir/bictegravir - Gilead Sciences; Lenacapavir/bictegravir oral combination - Gilead SciencesLatest Information Update: 11 Oct 2024
At a glance
- Originator Gilead Sciences
- Class Acetamides; Alkynes; Antiretrovirals; Antivirals; Chlorobenzenes; Fluorinated hydrocarbons; Oxazepines; Pyrazines; Pyrazoles; Pyridines; Pyridones; Sulfonamides; Sulfones
- Mechanism of Action Capsid protein inhibitors; HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III HIV-1 infections
Most Recent Events
- 30 Sep 2024 Phase-II/III clinical trials in HIV-1 infections (In children, In adolescents) in USA (PO) (NCT06532656)
- 01 Aug 2024 Gilead Sciences plans a phase II/III trial for HIV-1 infections (In children, In adolescent) in August 2024 (PO) (NCT06532656)
- 25 Jul 2024 Adverse events data from a phase II/III ARTISTRY-1 trial in HIV-1 infections released by Gilead Sciences